

2019 Risk Radar: Biotechnology Sector

January 2019


kpmg.com/cn



The PRC and HK Governments has shown a strong desire to stimulate development in the biotechnology sector, with large grants earmarked for that sector. However, organisations face changing regulatory requirements, potential constraints on the use of patient data and fierce competition on a global playing field. These challenges are forcing organizations to re-examine their research, testing and manufacturing processes, go-to-market strategies and customer engagement models to take full advantage of new technologies, to accelerate growth and enhance shareholder value.

Key trends observed in the market impacting the industry in the Greater China region:

- New technologies (e.g. AI, RPA, 3D printing, Blockchain) are fueling changes in how research and production are carried out;
- HK stock exchange listing as an alternative avenue for fundraising, creating a publicly traded life sciences sector in Greater China; and
- Increased adoption of Medtech, wearables and other connected devices providing larger and more granular patient data sets for analysis and testing.



Contact us

Paul McSheaffrey

Partner, Internal Audit,
Risk and Compliance
KPMG China
+852 2978 8236
paul.mcsheaffrey@kpmg.com

Alva Lee

Partner, Internal Audit,
Risk and Compliance
KPMG China
+852 2143 8764
alva.lee@kpmg.com

Jianing Song

Partner, Internal Audit,
Risk and Compliance
KPMG China
+852 2978 8101
jianing.n.song@kpmg.com

Jeffrey Hau

Partner, Internal Audit,
Risk and Compliance
KPMG China
+852 2685 7780
jeffrey.hau@kpmg.com

Susanne Steyn

Director, Internal Audit,
Risk and Compliance
KPMG China
+852 2140 2317
susanne.steyn@kpmg.com

Karan Kumar

Director, Internal Audit, Risk
and Compliance
KPMG China
+852 2847 5166
karan.kumar@kpmg.com

Stephen Cheung

Associate Director,
Internal Audit,
Risk and Compliance
KPMG China
+852 2847 5068
sp.cheung@kpmg.com

Christopher Ingle

Associate Director,
Internal Audit,
Risk and Compliance
KPMG China
+852 2685 7807
christopher.ingle@kpmg.com

Paul Cheng

Associate Director,
Internal Audit,
Risk and Compliance
KPMG China
+852 2847 5075
paul.cheng@kpmg.com

Claudia Yu

Associate Director, Internal
Audit,
Risk and Compliance
KPMG China
+852 2685 7898
claudia.yu@kpmg.com

Claire Doherty

Associate Director,
Internal Audit,
Risk and Compliance
KPMG China
+852 2913 2526
claire.doherty@kpmg.com

Sean Cheng

Associate Director,
Internal Audit,
Risk and Compliance
KPMG China
+852 2847 5129
sean.cheng@kpmg.com

Gianfran Liu

Associate Director,
Internal Audit,
Risk and Compliance
KPMG China
+852 2847 5164
gianfran.liu@kpmg.com

Tan Jee Eu

Associate Director,
Internal Audit,
Risk and Compliance
KPMG China
+852 2847 5182
jeeeu.tan@kpmg.com

**Dagmar van
Steenbrugge**

Associate Director,
Internal Audit,
Risk and Compliance
KPMG China
+852 2847 5060
dagmar.vansteenbrugge
@kpmg.com



kpmg.com/cn/socialmedia

The information contained herein is of a general nature and is not intended to address the circumstances of any particular individual or entity. Although we endeavour to provide accurate and timely information, there can be no guarantee that such information is accurate as of the date it is received or that it will continue to be accurate in the future. No one should act on such information without appropriate professional advice after a thorough examination of the particular situation.

© 2019 KPMG Advisory (Hong Kong) Limited, a Hong Kong limited liability company and a member firm of the KPMG network of independent member firms affiliated with KPMG International Cooperative ("KPMG International"), a Swiss entity. All rights reserved. Printed in Hong Kong. The KPMG name and logo are registered trademarks or trademarks of KPMG International.